DOI: https://doi.org/10.22141/2307-1257.1.15.2016.71490

Use of Pharmacogenotyping and Dosage of Certain Drugs in the Urology and Nephrology

А.А. Melnik

Abstract


The article is devoted to the use of methods of pharmacogenetically and aspects of dosing of some drugs used in Nephrology and Urology. Described angiotensin converting enzyme inhibitors (aceis), beta-adrenoblockers (BAB), calcium channel blockers (CCB), diuretics.

References


Innocenti F. Pharmacogenomics: Methods and Protocols (Methods in Molecular Вiology) // Humana Press. — 2005. — 224 p.

Table of Pharmacogenomic Biomarkers in Drug Labeling // www.fda.gva/drugs/scienceresearch, Update 05/20/2015.

Kino T., Hatanaka H., Hashimoto H. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics // J. Antibiot. — 1987. — 40. — 1249-55.

Kino T., Hatanaka H., Miyata S. et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro // J. Antibiot. — 1987. — 40. — 1256-1265.

Gupta A.K., Adamiak A., Chow M. Tacrolimus: a review of its use forthe management of dermatoses // JEADV. — 2002. — 16. — 100-114.

Magee C.C., Denton M.D., Milford E.L. Immunosuppressive agents in organ transplantation // Hosp. Med. — 1999. — 60. — 364-369.

Iwata H., Nagano T., Toyo-oka K. et al. Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin // Int. Immunol. — 1994. — 6. — 93-99.

Pamala A. Jacobson, William S. Oetting, Ann M. Brearley, Robert Leduc, Weihau Guan, David Schladt, Arthur J. Matas, Vishal Lamba, Bruce A. Julian, Rosalyn B. Mannon, and Ajay Israni. Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium for DeKAF Investigators Transplantation.

Сычев Д.А. Фармакогенетическое тестирование: клиническая интерпретация результатов. Рекомендация для практикующих врачей. — М., 2011. — С. 89.

Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels // http://www.fda.gov/Drugs/ScienceResearch/ResearchArea

Becquemont L., Alfirevic A., Amstutz U., Brauch H., Jacqz78 Aigrain E., Laurent-Puig P., Molina M.A., Niemi M., Schwab M., Somogyi A.A., Thervet E., Maitland-van der Zee A.H., van Kuilenburg A.B., van Schaik R.H., Verstuyft C., Wadelius M., Daly A.K. Pharmacogeno­mics. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogeno­mics. — 2010 Jan. — 12(1). — 113-24.

Passey C., Birnbaum A.K., Brundage R.C., Oetting W.S., Israni A.K., Jacobson P.A. Dosing Equation for Tacrolimus Using Gene­tic Variants and Clinical Factors // Br. J. Clin. Pharmacol. — 2011 Jun 14.

Birdwell К.А., Decker В., Barbarino J.M., Peterson J.F., Stein C.M., Sadee W., Wang D., Vinks A.A., He Y., Swen J.J., Lee­der J.S., van Schaik R.H.N., Thummel K.E., Klein T.E., Caudle K.E. and MacPhee I.A.M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.

Бойцов С.А., Кириченко П.Ю., Кузнецов А.Е. и др. Исследование I/D полиморфизма гена ангиотензинпревращающего фермента и A/C полиморфизма гена рецепторов I типа ангиотензина II у больных с хронической сердечной недостаточностью различных функциональных классов, развившейся на фоне ИБС // Сердечная недостаточность. — 2006. — Т. 4, № 2. — С. 98-102.

Кукес В.Г., Сулеманов С.Ш., Сычев Д.А. I/D полиморфизм ангиотензин-превращающего фермента: фармакологические аспекты // Дальневосточный медицинский журнал. — 2006. — № 2. — С.107-110.

Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. — 2-е изд., перераб. и доп. — М.: ЗАО «Издательство БИНОМ»; СПб.: Невский диалект, 2002. — 926 с.

Metabolic Drug Interactions / Еditors Levy R.H., Thummel K.E., Trager W.F., Hansten P.D., Eichelbaum M. — Philadelphia: Lippincott Williams & Wilkins, 2000. — 793 p.

Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. — М.: Реафарм, 2004. — С. 18-27, 40-47.

Saxena R., Shaw G.L., Relling M.V. et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype // Hum. Mol. Ge­net. — 1994. — 3(6). — 923-926.

National Kidney Foundation. Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Executive summary. — New York: K/DOQI Learning System (KLS)TM, 2002. — 94 p.

Al-Eisa A. Angiotensin converting enzyme gene insertion/deletion polymorphism in idiopathic nephrotic syndrome in Kuwaiti Arab children / A. Al-Eisa, M.Z. Haider // Strivastva Scand. J. Urol. Nephrol. — 2001. — Vol. 35. — P. 239-242.

Oktem F. et al. ACE I/D gene polymorphism in primary FSGS and steroid-sensitive nephrotic syndrome // Pediatr. Nephrol. — 2004. — Vol. 19. — P. 384-389.

Genetic polymorfisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children / Y. Frishberg et al. // Kidney Int. — 1998. — Vol. 54, № 6. — P. 1843-1849.

Siegsmund M., Brinkman U., Schaflefer E. et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism eith the susceptibility to renal epethelia tumors // J. Am. Soc. Nephrol. — 2002. — 13(7). — 1847-1854.

Brugts J.J., Boersma E., Simoons M.L. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit // Pharmacogenomics. — 2010. — 11(8). — 1115-26 [Review].




Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта